ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
ZIOPHARM Oncology, Inc., or the Company, held its 2017 annual
meeting of stockholders on June14, 2017, at which all proposals
properly brought before the meeting and requiring approval were
approved by the requisite vote. The final results of the voting
with respect to each proposal are set forth below.
(1) The stockholders elected six directors to serve as members of
the Companys board of directors until the next annual meeting of
the stockholders. The stockholders present in person or by proxy
cast the following numbers of votes in connection with the
election of directors, resulting in the election of all proposed
director nominees:
|
Nominee |
For | Withheld | BrokerNon-Votes | |||||||||
|
Sir Murray Brennan, M.D., GNZM |
40,989,025 | 8,521,383 | 63,470,475 | |||||||||
|
James A. Cannon |
42,760,768 | 6,749,640 | 63,470,475 | |||||||||
|
Senator Wyche Fowler, Jr. |
42,701,365 | 6,809,043 | 63,470,475 | |||||||||
|
Randal J. Kirk |
47,437,743 | 2,072,665 | 63,470,475 | |||||||||
|
Scott Tarriff |
42,171,079 | 7,339,329 | 63,470,475 | |||||||||
|
Michael Weiser, M.D., Ph.D. |
39,398,527 | 10,111,881 | 63,470,475 |
There were no abstentions with respect to Proposal 1.
(2) The stockholders ratified the appointment of RSM US LLP as
the independent registered public accounting firm of the Company
for 2017.There were 110,874,351 votes cast for the proposal;
1,151,293 votes were cast against the proposal; 955,239 votes
abstained; and there were no broker non-votes.
(3) The stockholders approved, on a non-binding advisory basis,
the compensation of the Companys named executive officers, as
disclosed in the Companys proxy statement for the 2017 annual
meeting. There were 42,010,077 votes cast for the proposal;
6,492,872 votes were cast against the proposal; 1,007,459 votes
abstained; and there were 63,470,475 broker non-votes.
(4) The stockholders recommended, on a non-binding advisory basis,
the preferred frequency for the solicitation of future advisory
stockholder approval of the compensation of the Companys named
executive officers be held every year, based on the following
votes. There were 47,607,659 votes cast for one year; 414,354
votes cast for two years; 1,221,542 votes cast for three years;
and 266,853 votes abstained.
Consistent with
the stockholder voting results above and the recommendation of
the board of directors of the Company as disclosed in the
Companys proxy statement for the 2017 annual meeting, the board
of directors of the Company has determinedto solicit a
non-binding advisory vote on the compensation of the Companys
named executive officers every year until the next required
stockholder vote on thefrequencyof such non-binding advisory
vote, or until the board of directors of the Company determines
that a different frequency of such non-binding advisory vote is
in the best interest of the Companys stockholders.
About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.